Lomustine (cas 13010-47-4)
-
Add time:08/29/2019 Source:sciencedirect.com
Lomustine is a nitrosourea used for the treatment of cancer. An alkylating agent, lomustine differs from other members of this class in being relatively lipid soluble and therefore capable of crossing the blood-brain barrier. For this reason, lomustine is employed for the treatment of tumors located in the central nervous system …
We also recommend Trading Suppliers and Manufacturers of Lomustine (cas 13010-47-4). Pls Click Website Link as below: cas 13010-47-4 suppliers
Prev:Electrochemical behaviour of anticancer drug Lomustine (cas 13010-47-4) and in situ evaluation of its interaction with DNA
Next:ArticlesRegorafenib compared with Lomustine (cas 13010-47-4) in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- ArticlesSingle-agent bevacizumab or Lomustine (cas 13010-47-4) versus a combination of bevacizumab plus Lomustine (cas 13010-47-4) in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial09/04/2019
- Short communicationA stability-indicating liquid chromatographic method for Lomustine (cas 13010-47-4)09/03/2019
- ArticlesLomustine (cas 13010-47-4)-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial09/02/2019
- Original ArticleCombination toceranib and Lomustine (cas 13010-47-4) shows frequent high grade toxicities when used for treatment of non-resectable or recurrent mast cell tumours in dogs: A European multicentre study09/01/2019
- Spectroscopic analysis of the interaction of Lomustine (cas 13010-47-4) with calf thymus DNA08/31/2019
- ArticlesRegorafenib compared with Lomustine (cas 13010-47-4) in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial08/30/2019
- Electrochemical behaviour of anticancer drug Lomustine (cas 13010-47-4) and in situ evaluation of its interaction with DNA08/28/2019
